Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment for Hepatitis B Relapse After Functional Cure (PEG-IFNα-2b)
ChiCTR2500107748Phase 4Not yet recruiting
- Sponsor
- Tianjin Third Central Hospital
- Start
- Aug 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (5 cohorts), sponsored by Tianjin Third Central Hospital. Primary endpoint: HBsAg clearance rate at 48 weeks of retreatment. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2500107748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107748.